Fenwick Represents LakePharma in Pending Acquisition by Curia

Fenwick represented LakePharma Inc., a privately held biologics drug discovery, clinical research, development and manufacturing organization, in its pending acquisition by Curia, formerly AMRI, a leading contract research, development and manufacturing organization.

The transaction, which is subject to customary closing conditions, is expected to close in the third quarter of 2021. After the transaction closes, the combined company will provide deep expertise in both large and small molecules from drug discovery through drug substance manufacturing, sterile injectable formulation and fill-finish production. More information can be obtained from LakePharma’s announcement.

The Fenwick transaction team included corporate partners Doug Cogen and David Michaels; corporate associate Victoria Lupu and law clerk Kaylee Johnson; executive compensation and employee benefits partner Gerald Audant and counsel Nicholas Frey; technology transactions partner Stefano Quintini and associates Sophia Chen and Kehl Sink; and tax partner Larissa Neumann.